Trials / Completed
CompletedNCT06820203
Premixed, Sequential and Manually Mixed Administration of Intrathecal Fentanyl and Bupivacaine in Cesarean Section
Comparison Between Premixed, Sequential and Manually Mixed Administration of Intrathecal Fentanyl and Bupivacaine in Cesarean Section: A Randomized Controlled Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to distinguish between premixed, sequential, and manually mixed administration of intrathecal fentanyl and bupivacaine in cesarean section.
Detailed description
Cesarean section (CS) is a lifesaving procedure when there is both maternal and fetal problems. The rate of CS increases dramatically from time to time. Regional anesthesia techniques are highly preferred for CS compared to general anesthesia. Coadministration of intrathecal opioids and local anesthetics (LAs) have been found to produce a potent intra and postoperative analgesic synergism without further depression of efferent sympathetic activity, hence results in less adverse hemodynamic effects, even with sub-therapeutic doses of LAs. Fentanyl has been considered the intrathecal LAs adjuvant of choice owing to its potency, fast onset and short duration of action, and lower incidence of respiratory depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl and Bupivacaine | Patients will receive premixed intrathecal fentanyl and bupivacaine in the same syringe. |
| DRUG | Fentanyl and Bupivacaine | Patients will receive intrathecal fentanyl and bupivacaine in separate syringes. |
| DRUG | Fentanyl and Bupivacaine | Patients will receive manually mixed intrathecal fentanyl and bupivacaine in the same syringe. |
Timeline
- Start date
- 2025-02-12
- Primary completion
- 2025-07-15
- Completion
- 2025-07-15
- First posted
- 2025-02-11
- Last updated
- 2025-07-25
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06820203. Inclusion in this directory is not an endorsement.